This prognostic signature successfully verified the chemopreventive effect of erlotinib, a small molecule EGF pathway inhibitor, in multiple rodent models [140], and also led to the initiation of a cancer chemoprevention clinical trial (NCT02273362). The gene discussed is EGF; the disease is cancer.